Literature DB >> 9258527

Simultaneous influenza and pneumococcal vaccination in elderly individuals.

G Grilli1, L Fuiano, L R Biasio, F Pregliasco, A Plebani, M Leibovitz, A G Ugazio, F Vacca, M L Profeta.   

Abstract

The study was performed to evaluate the effects of influenza and pneumococcal vaccines administered alone or in combination. 124 elderly subjects living in community were vaccinated either with influenza split vaccine or with pneumococcal 23-valent or with both vaccines at the same time in different sites. Sera were tested for hemoagglutination inhibiting antibodies for influenza and for antibodies against 23-valent vaccine for streptococcus pneumoniae. No side effects were observed in the vaccinated population. Serological results indicated that influenza vaccine increased significantly antibody levels. No difference was observed between the group which received influenza vaccine alone and that which received influenza and pneumococcal vaccines associated, considering either G.M.T or the percentages of protected individuals or the percentages of subjects who seroconverted. When pneumococcal vaccine was administered at the same time with influenza vaccine, there was a not statistically significant reduction in both mean antibody concentration and mean fold increase. It is concluded that the simultaneous administration of influenza and pneumococcal vaccines to elderly individuals, including subjects at risk, is safe, effective and economically advantageous.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9258527     DOI: 10.1023/a:1007398606807

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  16 in total

1.  Relation of chronic disease and immune response to influenza vaccine in the elderly.

Authors:  P A Gross; G V Quinnan; M E Weksler; U Setia; R G Douglas
Journal:  Vaccine       Date:  1989-08       Impact factor: 3.641

Review 2.  Modern vaccines. Pneumococcus and influenza.

Authors:  F Shann
Journal:  Lancet       Date:  1990-04-14       Impact factor: 79.321

3.  Protective efficacy of pneumococcal polysaccharide vaccines.

Authors:  P Smit; D Oberholzer; S Hayden-Smith; H J Koornhof; M R Hilleman
Journal:  JAMA       Date:  1977-12-12       Impact factor: 56.272

4.  Pneumococcal vaccine: dose, revaccination, and coadministration with influenza vaccine.

Authors:  A J Carlson; W L Davidson; A A McLean; P P Vella; R E Weibel; A F Woodhour; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1979-09

5.  Relative antigenicity in mice of H1N1, H3N2 and B strains present in inactivated influenza virus vaccines.

Authors:  M L Profeta; M Ruggeri
Journal:  Eur J Epidemiol       Date:  1987-03       Impact factor: 8.082

6.  Extensive deletion of immunoglobulin heavy chain constant region genes in the absence of recurrent infections: when is IgG subclass deficiency clinically relevant?

Authors:  A Plebani; A G Ugazio; A Meini; L Ruggeri; A Negrini; A Albertini; M Leibovitz; M Duse; A Bottaro; R Brusco
Journal:  Clin Immunol Immunopathol       Date:  1993-07

7.  [Hemagglutination inhibition test for influenza viruses with antigens treated with tween-ether].

Authors:  M Profeta; P Ballerini
Journal:  Ann Sclavo       Date:  1981 Sep-Dec

8.  Monitoring of the response of elderly individuals to pneumococcal vaccination with the aid of a novel ELISA.

Authors:  M Fattal-German; B Bizzini
Journal:  Eur J Epidemiol       Date:  1990-12       Impact factor: 8.082

9.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors:  E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

10.  Prevention and control of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1995-04-21
View more
  5 in total

1.  Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.

Authors:  Robert W Frenck; Alejandra Gurtman; John Rubino; William Smith; Martin van Cleeff; Deepthi Jayawardene; Peter C Giardina; Emilio A Emini; William C Gruber; Daniel A Scott; Beate Schmöle-Thoma
Journal:  Clin Vaccine Immunol       Date:  2012-06-27

2.  Quadrivalent cell culture influenza virus vaccine. Comparison to egg-derived vaccine.

Authors:  Alberto Pérez-Rubio; Julio Ancochea; Jose María Eiros Bouza
Journal:  Hum Vaccin Immunother       Date:  2020-04-07       Impact factor: 3.452

3.  Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.

Authors:  Kei Nakashima; Masahiro Aoshima; Satoko Ohfuji; Satoshi Yamawaki; Masahiro Nemoto; Shinya Hasegawa; Satoshi Noma; Masafumi Misawa; Naoto Hosokawa; Makito Yaegashi; Yoshihito Otsuka
Journal:  Hum Vaccin Immunother       Date:  2018-05-14       Impact factor: 3.452

Review 4.  Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: A meta-analysis.

Authors:  Yan-Yang Zhang; Xue-Feng Tang; Chang-Hui Du; Bin-Bing Wang; Zhen-Wang Bi; Bi-Rong Dong
Journal:  Hum Vaccin Immunother       Date:  2016-09-14       Impact factor: 3.452

5.  Potential impact of combined influenza and pneumococcal vaccines on the severity of respiratory illness in COVID-19 infection among type 2 diabetic patients.

Authors:  Amr Shaaban Hanafy; Waseem M Seleem; Hany A Elkattawy
Journal:  Clin Exp Med       Date:  2022-01-22       Impact factor: 5.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.